Total submissions: 3
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Genetic Services Laboratory, |
RCV000147297 | SCV000194670 | pathogenic | Iron accumulation in brain | 2014-03-17 | criteria provided, single submitter | clinical testing | |
Fulgent Genetics, |
RCV002505128 | SCV002816906 | pathogenic | Infantile neuroaxonal dystrophy; Neurodegeneration with brain iron accumulation 2B; Autosomal recessive Parkinson disease 14 | 2021-11-05 | criteria provided, single submitter | clinical testing | |
Broad Center for Mendelian Genomics, |
RCV002514835 | SCV003760982 | likely pathogenic | PLA2G6-associated neurodegeneration | 2023-01-24 | criteria provided, single submitter | curation | The p.Leu560fs variant in PLA2G6 has been reported in 3 individuals, in the compound heterozygous state, with PLA2G6-associated neurodegeneration (PMID: 27378808, 31196701, 24745848) and has been identified in 0.0009% (1/113656) of European (non-Finnish) chromosomes by the Genome Aggregation Database (gnomAD, http://gnomad.broadinstitute.org; dbSNP ID: rs587784336). Although this variant has been seen in the general population in a heterozygous state, its frequency is low enough to be consistent with a recessive carrier frequency. This variant has also been reported in ClinVar (Variation ID#: 159742) and has been interpreted as pathogenic by Genetic Services Laboratory (University of Chicago). This variant is predicted to cause a frameshift, which alters the protein’s amino acid sequence beginning at position 560 and leads to a premature termination codon 5 amino acids downstream. This alteration is then predicted to lead to a truncated or absent protein. Loss of function of the PLA2G6 gene is an established disease mechanism in autosomal recessive PLA2G6-associated neurodegeneration. In summary, although additional studies are required to fully establish its clinical significance, this variant is likely pathogenic for autosomal recessive PLA2G6-associated neurodegeneration. ACMG/AMP Criteria applied: PVS1, PM2 (Richards 2015). |